drugset / Trial / NCT02194322
Safety, Tolerability and Pharmacokinetics After Administration of Increasing Dose of BIBN 4096 BS in Healthy Male and Female Volunteers
RandomizedSingle-groupDouble-blindTreatment
Summary
The objective of the present study is to obtain information about the safety, tolerability and pharmacokinetics of BIBN 4096 BS after single intranasal administration of increasing doses in healthy male and female volunteers
Timeline
- Start
- 2001-11
- Primary completion
- 2002-01
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OLCEGEPANT | Small molecule | 6.25 mg | Intranasal |
| Subject | OLCEGEPANT | Small molecule | 200 mg | Intranasal |
Indications
No indication recorded.